Table 3.
Characteristic | Regular Menses de novo (n = 17) | Sustained OM (n = 13) | p-Value |
---|---|---|---|
Age at follow-up (years) | 37.60 (35.0–42.2) | 34.4 (29.7–34.9) | 0.07 |
BMI at follow-up (kg/m2) | 24.8 (21.07–31.69) | 32.47 (23.98–39.13) | 0.04 |
BMI at baseline (kg/m2) | 22.85 (21.45–27.82) | 29.14 (25.46–36.77) | 0.07 |
Waist circumference at follow-up (cm) | 84 (75–97) | 105 (90–126) | 0.01 |
Waist circumference at baseline (cm) | 77 (71–80) | 93 (79–110) | 0.02 |
Fat mass at follow-up (%) | 31.3 (22.7–37.5) | 45 (32.7–50) | 0.008 |
Fat mass at baseline (%) | 32 (27.5–38.5) | 42 (29.6–48.1) | NS |
Glucose 0′ at follow-up (mg/dL) | 90 (89–102) | 101 (94.00–103.00) | NS |
Glucose 0′ at baseline (mg/dL) | 83 (78–89) | 86.1 (81–88) | NS |
Mean glucose at follow-up (mg/dL) | 102.25 (97.25–123.75) | 138.5 (123–152) | 0.004 |
Mean glucose at baseline (mg/dL) | 100.5 (91.25–113) | 118 (102.25–125.75) | NS |
Insulin 0′ at follow-up (uIU/mL) | 7.73 (6.15–11.54) | 16.75 (9.44–19.57) | 0.008 |
Insulin 0′ at baseline (uIU/mL) | 10.53 (7.4–14.54) | 18.5 (11.7–25.8) | 0.05 |
Mean insulin at follow-up (uIU/mL) | 45.61 (35.55–52.66) | 78.09 (58.64–105.37) | 0.02 |
Mean insulin at baseline (uIU/mL) | 54.5 (37.55–83.25) | 102.15 (66.63–116.93) | 0.02 |
M-clamp value at baseline (mg/kgffm/min) | 9.84 (8.4–11.99) | 5.83 (4.17–7.92) | 0.006 |
Matsuda index at follow-up | 5.27 (3.06–6.56) | 1.99 (1.57–3.41) | 0.008 |
Matsuda index at baseline | 4.23 (2.71–6.42) | 1.83 (1.59–3.4) | 0.02 |
Prediabetes at follow-up n (%) | 5 (29.41%) | 9 (69.23%) | 0.03 |
Triglycerides at follow-up (mg/dL) | 63 (50–97) | 113 (74–210) | 0.01 |
Triglycerides at baseline (mg/dL) | 74 (51–92) | 109.2 (76–172) | NS |
LDL-c at follow-up (mg/dL) | 111.4 (100.4–117.6) | 104 (101–110) | NS |
LDL-c at baseline (mg/dL) | 92.8 (78.2–139.8) | 99 (88.4–127.4) | NS |
HDL-c at follow-up (mg/dL) | 68.0 (56.0–71.0) | 50 (42–100) | NS |
HDL-c at baseline (mg/dL) | 58.2 (53.0–69.0) | 56 (43–66) | NS |
HsCRP at follow-up (mg/L) | 0.38 (0.26–1.06) | 3.49 (1.09–6.16) | 0.003 |
HsCRP at baseline (mg/L) | 0.94 (0.14–1.61) | 2.13 (1.47–4.76) | 0.01 |
E-selectin at follow-up (ng/mL) | 10.6 (9.3–12.49) | 16.42 (13.22–30.67) | 0.009 |
E-selectin at baseline (ng/mL) | 27.2 (16.72–36.15) | 39.23 (26.59–55.94) | 0.04 |
Systolic blood pressure at follow-up (mmHg) | 122 (109–125) | 130 (122–135) | 0.01 |
Systolic blood pressure at baseline (mmHg) | 120 (110–125) | 120 (110–130) | NS |
Metabolic syndrome according to IDF at follow-up n (%) | 3 (17.65%) | 8 (61.54%) | 0.01 |
Metabolic syndrome according to IDF at baseline n (%) | 1 (5.88%) | 5 (38.46%) | 0.03 |
FSH at follow-up (mIU/mL) | 6.65 (5.5–7.99) | 5.08 (4.55–5.26) | 0.02 |
FSH at baseline (mIU/mL) | 6.9 (5.6–7.6) | 4.9 (3.64–5.9) | 0.04 |
LH/FSH at follow-up | 0.65 (0.49–0.87) | 1.27 (0.81–1.88) | 0.004 |
LH/FSH at baseline | 1.14 (0.79–1.44) | 1.96 (1.29–2.26) | 0.01 |
TT at follow-up (ng/mL) | 0.39 (0.32–0.48) | 0.58 (0.5–0.74) | 0.01 |
TT at baseline (ng/mL) | 0.57 (0.45–0.71) | 0.77 (0.61–1.06) | NS |
SHBG at follow-up (nmol/L) | 51.79 (37.66–66.32) | 29.34 (23.36–105.09) | NS |
SHBG at baseline (nmol/L) | 45.13 (34.35–60.90) | 27.20 (20.45–54.42) | NS |
AMH at follow-up (ng/mL) | 2.51 (1.49–3.45) | 8.14 (7.44–12.13) | 0.0009 |
AMH at baseline (ng/mL) | 7.24 (5.46–9.45) | 11.28 (9.91–13.88) | 0.04 |
Attempts of pregnancy a (months) | 2 (1–12) (n = 11) | 42 (18–66) (n = 8) | 0.02 |
OM, oligomenorrhea; SHBG, sex hormone-binding globulin; TT, total testosterone. Data are expressed as median (25–75% quartiles) or numbers (%). p < 0.05 was considered statistically significant. a The period between the beginning of trying for a baby and confirmation of a pregnancy, assessed only in the women who gave birth. Abbreviations: AMH, anti-Müllerian hormone; BMI, body mass index; FSH, follicle-stimulating hormone; HDL-c, high-density lipoprotein cholesterol; HOMA-%β, homeostasis model assessment β-cell function; hsCRP, high-sensitivity C-reactive protein; IDF, International Diabetes Federation; LDL-C, low-density lipoprotein cholesterol; LH, luteinizing hormone; M-clamp value, insulin sensitivity estimated with the euglycemic hyperinsulinemic clamp technique; NS, statistically nonsignificant.